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ABSTRACT 
Fish oil (FO) is a potent anti-inflammatory and lipid-lowering agent.  Because inflammation can modulate 
lipid metabolism and vice versa, we hypothesized that combining FO with cyclooxygenase inhibitors 
(COXIBs), well-known anti-inflammatory drugs, can enhance the anti-inflammatory and lipid-lowering 
effect of FO.  LDLR-/- mice were fed a high fat diet supplemented with 6% olive oil or FO for 12 wk in 
the presence or absence of indomethacin (Indo, 6mg/liter drinking water).  FO reduced plasma total 
cholesterol by 30% but in combination with Indo, exerted a greater decrease (44%).    The reduction of 
liver cholesterol ester (CE) and triglycerides (TG) by FO (63% and 41%, respectively) was enhanced by 
Indo (80% in CE and 64% in TG).  FO + Indo greatly increased the expression of genes modulating lipid 
metabolism and reduced the expression of inflammatory genes compared to control.  The mRNA and/or 
protein expression of pregnane X receptor (PXR) and cytochrome P450 (CYP 450) isoforms that alter 
inflammation and/or lipid metabolism are increased to a greater extent in mice that received FO + Indo.  
Moroever, the nuclear level of PXR is significantly increased in FO + Indo group.  Combining FO with 
COXIBs may exert their beneficial effects on inflammation and lipid metabolism via PXR and CYP 450s.     
Supplementary key words: n-3 fatty acids, cytochrome P450s, COXIBs, PXR, cholesterol, triglycerides 
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INTRODUCTION 
Dyslipidemia characterized by elevated cholesterol or triglycerides is a major risk factor for coronary 
heart disease (CHD) (reviewed in (1)).  One of the most studied forms of dyslipidemia is familial 
hypercholesterolemia (FH) caused by genetic factors.  Although homozygous FH is a rare condition, 
heterozygous FH occurs approximately 1 in 500 people and can cause premature atherosclerotic disease 
(Reviewed in (2)).  Combination therapy is being commonly employed in clinical practice to improve 
hypercholesterolemia.  The most commonly used combination therapy consists of statins with fibrates or 
niacin.  However, this combination has limited additive effect on LDL cholesterol levels.  Moreover, the 
poor tolerance of niacin and statin-induced side effects like muscle toxicity limit the use of this 
combination (Reviewed in (3, 4)).  In addition to dyslipidemia, inflammation by itself can lead to 
increased risk of CHD.  Therefore, a therapeutic regimen that has the potential to reduce both 
dyslipidemia and inflammation would be more beneficial in reducing cardiovascular events than 
treatments aimed at improving dyslipidemia alone.  
 
Fish oil (FO) containing the n-3 polyunsaturated fatty acids such as eicosapentaenoic acid (EPA) and 
docosahexaenoic acid (DHA) is a potent anti-inflammatory (reviewed in (5)) and triglyceride (TG) 
lowering agent (6).     In addition to its TG lowering effect, FO has also been reported to reduce LDL 
cholesterol levels in both FH and normal subjects (7).  Case reports have shown that FO may be 
beneficial to children having FH (8).  Moreover, we (9) and others (10) have shown that FO reduces 
plasma cholesterol levels in LDLR-/- mice, a model for FH.  Although FO is a safe alternative to other 
hypolipidemic agents, it only exerts a modest cholesterol-lowering effect and therefore very high doses 
are needed.  Thus, it is important to develop a strategy to improve the therapeutic efficacy of FO. 
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The liver plays a central role in regulating plasma lipid levels and it is becoming clear that inflammatory 
events in the liver may modulate hepatic lipid metabolism.  For example, it has been shown that increased 
inflammatory response in liver resident macrophages, or Kupffer cells, promotes the development of 
hepatic steatosis and that elimination of these activated resident Kupffer cells is associated with reduced 
hepatic steatosis (11, 12).  Futhermore, several anti-inflammatory agents have been shown to promote 
hepatic lipid metabolism.  For example, dietary components such as curcumin, baicalin and capsaicin 
with known anti-inflammatory properties have been shown to ameliorate metabolic disorders and hepatic 
steatosis (13-15). With regard to dietary FO, another anti-inflammatory agent, we and others have 
reported that FO or the n-3 fatty acids can ameliorate hepatic steatosis (9, 16) and improve dyslipidemia.   
Taken together, these reports suggest that several anti-inflammatory agents have the propensity to 
promote lipid catabolism in liver.   
 
FO and Indo both mediate their anti-inflammatory effects by modulating arachidonic acid (AA) 
metabolism.  For example, Indo inhibits COX-mediated production of 2-series eicosanoids from AA 
which are mostly pro-inflammatory.   Alternatively, the n-3 fatty acids replace AA from the membrane 
phospholipids thereby reducing the availability of AA to COX thus reducing the production of 2-series 
eicosanoids from AA.  It should also be noted that the n-3 fatty acids by themselves can be metabolized 
by COX giving rise to 3-series eicosanoids that are anti-inflammatory or less pro-inflammatory compared 
to AA-derived 2-series eicosanoids (17).  Overall, the n-3 fatty acids and COXIBs act through modulating 
AA metabolism.  Because of their overlapping effect on AA metabolism it was postulated that a 
combination of n-3 fatty acids and cyclooxygenase inhibitors (COXIBs) may exert an enhanced anti-
inflammatory effects.  In fact, a synergistic anti-inflammatory effect of this combination has been 
reported in monocytes (18).  Moreover, Serhan et al have shown that aspirin, a COX inhibitor, triggers 
the formation of potent anti-inflammatory agents called resolvins from n-3 fatty acids (19).  However, the 
efficacy of this combined therapy in modulating hepatic inflammatory response and/or lipid accumulation 
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is unknown.   Because inflammation can modulate lipid metabolism, we hypothesized that combining fish 
oil with COXIBs may exert enhanced anti-inflammatory and lipid-lowering effects.   
 
LDLR-/- mice, a model for FH, are widely used to study dyslipidemia and atherosclerosis.  Using this 
model we studied the effects of dietary FO on hepatic steatosis and dyslipidemia in the presence or 
absence of Indo, an isoform non-specific COXIB.  We demonstrate that FO in the presence of Indo exerts 
synergistic anti-inflammatory and lipid-lowering effects in the liver, which is associated with enhanced 
hypolipidemic effects in plasma.  The findings will have implications in developing a therapeutic strategy 
to improve the efficacy of dietary fish oil in alleviating dyslipidemia and hepatic steatosis in 
hyperlipidemic patients who are at an increased risk of premature CVD mortality.   
MATERIALS AND METHODS 
Mice:  LDLR-/- mice originally obtained from Jackson Laboratories were used in the present study.  Two 
to three month old female LDLR-/- mice were fed a high fat diet (39% KJ from fat) supplemented with 
6% (by weight) olive oil or FO and 0.5% cholesterol for 12 wk in the presence or absence of Indo 
(6mg/liter) (20) in drinking water.  A stock of Indo was made in DMSO which is then mixed in drinking 
water.  The water containing Indo was changed every day.  The olive oil, and FO alone fed mice received 
DMSO as a vehicle control in their drinking water.  We have published the composition of the diet in 
detail previously (9).  Cumulative food intake was measured in 2 cages of mice per group.  At the end of 
12 wk, the mice were fasted for 5 h and sacrificed by isoflurane overdose followed by cervical 
dislocation.  All animal care procedures were carried out with approval from the Institutional Animal 
Care and Use Committee of Vanderbilt University, Virginia Tech, and VA Nebraska Western Iowa 
Health Care System, Omaha. 
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Plasma measurements:  Plasma total cholesterol (TC) and triglycerides (TG) were analyzed using kits 
from Raichem.  Plasma free fatty acids (FFA) were measured using kits from Wako chemicals.  Plasma 
levels of cholesterol ester (CE), free cholesterol (FC) and phospholipids (PL) were analyzed by gas 
chromatography (GC) at the Lipid Core Laboratory.  Blood glucose was measured using a Lifescan 
glucometer from Johnson and Johnson.  Plasma insulin measurements were performed using an insulin 
assay kit (Linco Research). The homeostasis model assessment of insulin resistance (HOMA-IR) was 
used as a measure of insulin resistance and was calculated using the following equation: HOMA-IR = 
fasting serum insulin (μU/mL) × fasting serum glucose (mg/dL)/405.  Plasma lipoprotein profiles were 
analyzed by fast protein liquid chromatography (FPLC) using superose 6 column (Amersham Pharmacia).  
One hundred µl of pooled plasma samples were loaded onto the column and forty 0.5 ml fractions were 
collected for cholesterol measurement.  Fractions 15-20 contain VLDL, 21-26, LDL and 27-34, HDL. 
Lipid analysis:  The levels of cholesterol ester (CE) and TG in liver samples were determined by gas 
chromatography at the Lipid Core Laboratory of Vanderbilt University. 
Microarray analysis:  The microarray analysis of liver RNA samples were carried out using pooled RNA 
samples (6 samples per group) at the Functional Genomics Shared Resouces at Vanderbilt University.  
Further details for the experimental procedures are provided in the online supplemental data.   
Real-time PCR:  Total RNA was extracted from liver, perigonadal adipose tissue, and brown adipose 
tissue (BAT) samples using TRIzol reagent (Invitrogen) and cDNA synthesis was carried out using 
iScript cDNA synthesis kit from Bio-rad.  Real-time PCR analysis was performed for genes involved in 
lipid metabolism and inflammatory response using applied on-demand primer-probes from Applied 
Biosystems.  We have used CT method to quantify the mRNA expression levels.  Except for low 
expression genes (inflammatory genes), we have set the number of cycles as 36.  
Western blot analysis:  Liver samples were homogenized in lysis buffer containing 20 mmol/L Tris-HCl 
(pH 8.0), 150 mmol/L NaCl, 1 mmol/L EDTA, 1 mmol/L EGTA, 0.5% NP-40, 2.5 mmol/L sodium 
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pyrophosphate, 1 mmol/L sodium orthovanadate and protease inhibitor cocktail (Roche).  The gels were 
immunoblotted for PXR, CYP 3A, and CYP 4A.  To confirm equal loading, blots were also probed with 
GAPDH antibody.  Because the isoform specific antibodies for CYP 3A44 and 4A10 are not available, 
we used general antibodies for CYP 3A and CYP 4A in our study.  We purchased the antibodies for 
pregnane X receptor (PXR), CYP 3A, and CYP 4A from Santacruz Biotech.  GAPDH antibody was 
purchased from cell signaling.   
Preparation of nuclear extracts:  The nuclear extracts were prepared from liver samples as reported 
previously (21).  We performed western blot analysis using the nuclear extracts to determine the nuclear 
translocation of  PPARα and PXR using anti-PPARα and anti-PXR antibodies, respectively (Santacruz 
Biotech).  We used TATA binding protein (TBP) as a loading control and anti-TBP antibody was 
purchased from ABCAM.   
Measures of fatty acid oxidation.  Fatty acid oxidation was measured in whole liver homogenates by 
measuring and summing 14CO2 production and 14C-labeled acid-soluble metabolites from the oxidation of 
[1-14C]-palmitic acid as previously described (22-24).   
Triglyceride secretion rate:  The TG secretion rate was measured as described earlier (25).  At the end of 
the experimental period, the mice were fasted overnight and baseline blood samples were collected from 
anesthetized mice through tail vein bleeding.  The mice were then injected intravenously with tyloxapol 
(Triton), a lipoprotein lipase inhibitor, purchased from Sigma, at a concentration of 500 mg/kg body 
weight.  The blood samples were collected from tail vein every 1 h up to 3 h and plasma was isolated for 
TG analysis.  The slope of the line from 0 h to 3 h was used to calculate TG production rate.   
Eicosanoid measurements:   Eicosanoids such as prostaglandin E2 (PGE2), prostaglandin E3 (PGE3), 
thromboxane B2 (TXB2), and thromboxane B3 (TXB3) in liver were analyzed by gas chromatography 
(GC)/mass spectrometry (MS) at the Eicosanoid Core Laboratory of Vanderbilt University.  Please see the 
online supplemental data for details of this experiment.   
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Measurement of COX-1 activity in whole blood:  COX-1 activity in whole blood was measured as 
previously described (26).  Briefly, 200 µl of blood samples collected in heparin (19 units/ml) at the time 
of sacrifice were stimulated with ionomycin (50 µM) for 30 min at 37C and centrifuged at 3000 rpm for 
5 min at 4C.  The plasma samples were collected and frozen at -80C immediately.  Analysis of TXB2 
and TXB3 was carried out using GC/MS at the Eicosanoid Core Laboratory at Vanderbilt University as 
described in the online-supplemental data.   
Statistical Analysis:  Values are presented as the mean ± SEM.  Data were analyzed with Prism Graphpad 
using one way ANOVA followed by Tukey’s post-hoc test to compare the responses among different 
groups.  A statistical probability of P<0.05 was considered significant.   
RESULTS 
Effect of dietary FO in the presence or absence of Indo on metabolic parameters:   
The body weight and liver weight of the mice did not change in any of the groups compared to control.  
The cumulative food intake was not altered much among different groups.  The fat mass as measured by 
NMR trended towards an increase in FO and FO + Indo groups.   However, the adiposity (% body 
weight) showed a significant increase in FO fed mice compared to olive oil fed control and Indo treated 
mice.  The adiposity was not altered in the Indo treated mice but the mice that received a combination of 
FO and Indo exhibited a trend towards an increase in adiposity.  The perigonadal adipose tissue (AT) did 
not change in FO or Indo treated mice but it increased significantly in mice that received both FO and 
Indo.  The blood glucose, plasma insulin, and HOMA-IR were not changed in any of the groups (Table 
1).     Plasma TC was significantly decreased in mice that received FO (P<0.001) or Indo (P<0.01) 
compared to olive oil fed control mice.  Interestingly, a more potent reduction in plasma TC was seen in 
mice that received both FO and Indo.  In fact, TC level was significantly reduced in FO + Indo treated 
mice compared to mice that received only the FO diet (P<0.05).   The CE level showed only a trend 
towards a decrease in FO fed mice.  However, a significant reduction in CE was noted in mice that 
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received FO + Indo compared to olive oil controls.  Thus mice receiving both FO and Indo showed more 
than 20% reduction in plasma TC and CE compared to mice that received FO only.  Plasma TG levels 
were decreased significantly in FO (P<0.001), Indo (P<0.01), and FO + Indo (P<0.001) treated mice.  
Thus, although the cholesterol lowering effect of FO was enhanced by combining with Indo, its TG 
lowering effect was not altered.  The plasma FFA levels were reduced significantly by FO in the absence 
(P<0.001) or presence (P<0.01) of Indo (Table 1).  These data indicate that while FO by itself exerts a 
potent cholesterol lowering effect in plasma, this effect is potentiated by Indo in LDLR-/- mice.  In 
addition, analysis of lipoprotein profile revealed that FO reduced both VLDL, and LDL cholesterol levels 
in LDLR-/- mice.  It is interesting to note that Indo by itself showed a moderate decrease in VLDL and 
LDL cholesterol levels.  In line with the plasma lipid profile, the levels of VLDL and LDL cholesterol 
were decreased to a greater extent in mice that received both FO and Indo (Figure 1).    
 
Effect of dietary FO in the presence or absence of Indo on hepatic steatosis: 
Analysis of hepatic lipid profile showed that FO by itself mediated a potent reduction in liver CE and TG 
as we reported earlier (9, 27).  Interestingly, Indo also mediated a significant reduction in both CE and TG 
accumulation however, to a lesser extent than FO.  Of note, FO + Indo exerted a more pronounced 
reduction in CE.  The TG lowering effect of FO in the liver was also moderately increased by Indo.  Thus, 
the CE and TG levels were 30% and 18% lower respectively, in mice that received FO plus Indo 
compared to mice that received only FO (Fig. 2A&B).  The levels of free cholesterol and free fatty acids 
were not altered significantly in any of the groups (Fig. 2C&D).  Taken together, these data demonstrate 
that FO reduces hepatic steatosis by reducing both CE and TG and this effect is enhanced by Indo.   
 
Effect of dietary FO in the presence or absence of Indo on hepatic gene profile:    
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Because lipid accumulation was more favorably reduced in mice that received FO + Indo, we next 
performed a microarray analysis (Microarray data GEO accession number: GSE23742)* to gain insight 
into the genes that are up or downregulated under this condition.  Overall, our data indicated that several 
genes modulating lipid metabolism, drug/lipid metabolism, and immune response were greatly altered 
upon combined therapy (Table 2 and Supplemental Tables 1 and 2).   
 
Effect of dietary FO in the presence or absence of Indo on genes involved in hepatic lipid metabolism: 
We performed a real time PCR analysis to evaluate the microarray data (Fig. 3A-H).  The expression of 
PPARα-targeted genes such as carnitine palmitoyl transferase-1 (CPT-1) and diacyl glycerol O-acyl 
transferase-1 (DGAT-1) was increased significantly in mice that received either Indo or a combination of 
FO + Indo.   Another PPARα-induced gene, long chain acyl coA synthetase-1 (ACSL-1), was 
significantly increased only in mice that received a combination of FO + Indo compared to olive oil-fed 
controls.  Importantly, we noted that certain genes involved in peroxisomal lipid metabolism were 
significantly increased in Indo and/or FO + Indo treated mice.  For example, the expression of acyl CoA 
oxidase (ACOX-1), the key regulatory enzyme of peroxisomal β-oxidation (28) was significantly 
increased only in mice that received the combination of FO and Indo (1.9-fold, P<0.01).  The expression 
of ATP-binding cassette transporter D3 (ABCD3) or the peroxisomal membrane protein 70 (PMP 70) 
which is involved in peroxisomal transport of fatty acids (29), was increased significantly in both Indo 
alone (2.6 fold) and FO + Indo (2.9 fold) treated mice (P<0.001).  Acyl CoA thioesterase-3 (ACOT-3), 
another gene involved in fatty acid metabolism in peroxisomes, was significantly upregulated in Indo and 
FO + Indo treated mice.  Overall, the expression of PPARα-targeted genes and peroxisomal genes was 
increased in Indo and/or FO + Indo treated mice and the combined treatment is more potent in this 
response.  Of note, the expression of lipogenic genes, in particular, FASN is significantly decreased in 
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Indo (P<0.01) and FO + Indo (P<0.001) treated mice.  The mRNA expression of ACC-1, another gene 
involved in de novo lipogenesis was not altered significantly.   
 
Effect of dietary FO in the presence or absence of Indo on genes involved in drug/lipid metabolism: 
Our microarray analysis revealed that various CYPs involved in drug or lipid metabolism were 
upregulated in mice that received FO in the presence of Indo (Table 2 and Supplemental Table 1).  We 
were able to confirm the microarray data using real-time PCR analysis which showed a significant 17.6- 
and 4-fold increase (P<0.05) in the expression of CYP 2C39 and CYP 2B10, respectively, in FO + Indo 
received mice compared to olive oil-fed control (Fig. 4A&B).   We also analyzed the mRNA expression 
of one player in bile acid synthesis, CYP 7A1 and noted that its expression was not altered significantly in 
any of the groups (Fig. 4C).  We next wanted to determine the protein levels of CYPs by western blot 
analysis.  The antibody for CYP2C39 is not commercially available and therefore, we could not verify the 
protein level of CYP 2C39 in our samples.  Western blot analysis of CYP 2B10 showed that this protein 
is not altered in FO + Indo treated mice (data not shown).  Because, our microarray data showed that PXR 
gene (Nr1i2) is upregulated in FO + Indo treated mice (Supplemental Table 1), we next analyzed the 
protein levels of PXR, a nuclear receptor that regulates the expression of several CYPs of 2C and 3A 
family.  We found that the protein expression of PXR was increased significantly in FO and Indo alone 
treated mice.  Moreover, PXR level was increased to a greater extent in FO + Indo treated group 
compared to the other groups.  Furthermore, in line with the microarray gene expression data, the protein 
levels of CYP 3A, a downstream target of PXR was significantly increased in FO + Indo treated mice.  
The protein expression of CYP4A, a PPARα target and another CYP shown to be upregulated in our 
microarray data also increased significantly in mice that received a combination of FO and Indo (Fig. 4D-
G).  Taken together, these data show that the expression of PXR several CYPs is greatly increased in mice 
that received a combination of FO and Indo.        
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Effect of dietary FO in the presence or absence of Indo on hepatic lipid metabolism and TG secretion rate: 
Because several PPARα and PXR target genes were upregulated in FO + Indo treated mice, we wanted to 
determine the activities of PPARα and PXR in liver samples.  Western blot analysis of nuclear extracts 
revealed that the activities of PPARα showed only a trend towards an increase in FO and FO + Indo 
treated mice.  On the other hand, the nuclear level of PXR was significantly increased in mice that 
received FO + Indo (Fig. 5A-C).  We next analyzed hepatic fatty acid oxidation by incubating liver 
homogenates in the presence of [14C] palmitic acid, and measuring and summing the levels of [14C]-CO2 
and 14C-labeled acid soluble metabolites.  CO2 production is indicative of complete oxidation of fatty 
acids, whereas acid soluble metabolites (ASMs) are a measure of the incomplete oxidation of fatty acids.  
Our data showed that the level of [14C]-CO2 is actually reduced significantly in FO and FO + Indo groups.  
On the other hand, we noted a mild but significant increase in the levels of ASMs in these two groups 
suggesting the potential involvement of peroxisomal fatty acid oxidation in these two groups.  
Nevertheless, the total palmitate oxidation, the sum of CO2 produced and ASMs, which is a measure of 
total β-oxidation, was not altered significantly in any of the groups (Fig. 5D-F).  Analysis of TG secretion 
rate revealed that the mice that received both FO and Indo secrete less TG than the control mice (Fig. 
5G). 
Effect of dietary FO in the presence or absence of Indo on the expression of genes involved in 
inflammation: 
We noted that the expression of MCP-1 was decreased significantly in mice that received FO (58%, 
P<0.01) or Indo (43%, P<0.05) individually.  Notably, an even further decrease in MCP-1 expression was 
seen in mice that received a combination of FO and Indo (80%, P<0.001, Fig. 6A).  Similarly, the 
expression of MIP-1α was significantly reduced in mice that received either FO (65%) or Indo (80%) 
compared to olive oil supplemented control (P<0.001).  A much greater decrease in MIP-1α (90%) was 
noted in mice that received a combination of FO and Indo (P<0.001, Fig. 6B).  Furthermore, the 
expression of MMP-12 was reduced significantly in FO or Indo received mice (P<0.001) and MMP-12 
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expression was almost abolished in mice that received FO + Indo (Fig. 6C).  The expression of IL-1α was 
decreased significantly in both FO and FO + Indo received mice (P<0.05, Fig. 6D).    Although the 
expression of tumor necrosis factor (TNFα), and serum amyloid A-1 (SAA-1), was not altered 
significantly when compared to olive oil control, the expression of these genes in FO + Indo treated mice 
was significantly reduced when compared to Indo treatment (Fig. 6E&F).   
Effect of dietary fish oil in the presence or absence of Indo on the mRNA expression of genes involved in 
inflammation or lipid metabolism in white and brown AT: 
Analysis of the white AT (perigonadal AT) showed that the mice that received the FO diet exhibited a 
trend towards a decrease in F4/80 and MCP-1, markers of macrophages and inflammation, respectively.  
However, the levels of these markers were not altered significantly in any of the groups (Fig. 7A&B).  
Moreover, none of the groups showed a significant difference in the expression levels of F4/80 and MCP-
1 in BAT as well (7 C&D).  To determine whether the enhanced lipid-lowering effect seen with FO + 
Indo treated groups may also be due to increased lipid metabolism in the BAT, we analyzed the mRNA 
expression of uncoupling protein-1 (UCP-1) and PPAR coactivator-1α (PGC-1α).  We noted that the 
expression of these two genes was not altered significantly in any of the groups compared to olive oil-fed 
control (Fig. 7 E&F).   
Effect of dietary FO in the presence or absence of Indo on the levels of COX-derived eicosanoids in liver: 
TXB2 and PGE2 are considered to be derived mainly from AA via COX-1, and -2 activities, respectively.  
To determine whether Indo, an isoform non-specific COXIB, does inhibit COX activity in our 
experimental condition, we next determined the levels of TXs and PGs.  We found that the levels of the 
AA-derived 2-series eicosanoids such as TXB2 and PGE2 were significantly reduced in the liver of mice 
that received FO or Indo individually or in combination (Fig. 8A&D, P<0.001).  It is interesting to note 
that FO was as potent as Indo in reducing the formation of these metabolites from AA.  Because the n-3 
fatty acids can also be metabolized by COX activity, it is plausible that the reduction in these 2-series 
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TXs and PGs may be associated with an increase in 3-series metabolites in FO fed mice.  To check this 
possibility, we also measured TXB3 and PGE3 in liver samples (Fig. 8B&E).  There was a trend towards 
an increase in TXB3 and PGE3 in FO fed mice although this effect was not significant.  Moreover, the 
magnitude of the formation of 3-series eicosanoids from FO was much less compared to 2-series 
metabolites derived from AA.  Thus, the cumulative levels of TXB2+TXB3 and PGE2+PGE3 were much 
less in FO fed mice compared to olive oil fed control (Fig. 8C&F).   Next, we determined COX activity in 
the plasma samples.  The plasma levels of TXB2 were significantly reduced in mice receiving either FO or 
Indo (Fig. 8G, P<0.001).  TXB2 formation was nearly abolished in mice that received both FO and Indo.  
Although FO feeding resulted in a significant increase in TXB3 levels, the magnitude of TXB3 production 
was far less compared to TXB2 formation from AA in olive oil control (Fig. 8H).  Thus, the level of TXB2 
in olive oil fed control mice (Fig. 8G) was 75 ng/ml and that of TXB3 in FO fed mice (Fig. 8H) was 2 
ng/ml.  The overall effect of FO on COX activity is further evident from the combined levels of 2- and -3 
series eicosanoids in plasma.  As noted in Fig. 8I, the cumulative levels of these eicosanoids were greatly 
decreased in FO fed mice compared to olive oil fed mice.  Thus, in addition to proving that COX activity 
is efficiently blocked by Indo, our data show that the n-3 fatty acids are not preferentially metabolized by 
COX pathways and that other pathways may be involved in mediating the anti-inflammatory effects of n-
3 fatty acids.   
  
DISCUSSION 
In the current study we tested the hypothesis that the lipid-lowering effects of FO can be enhanced by 
combining with COXIBs, in particular, Indo.  While FO is a well-known TG-lowering agent, we and 
others have shown that it also reduces plasma cholesterol levels (9, 10).  Along the lines, in the present 
study, we have demonstrated that FO leads to a remarkable decrease in both TG and TC levels in plasma 
(Table 1).  It is interesting to note that Indo alone leads to a significant decrease in plasma TC and TG in 
LDLR-/- mice (Table 1) and a marked reduction in VLDL cholesterol levels (Figure 1).  We have also 
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shown that the combination of FO and Indo leads to an overall enhancement in the lipid-lowering effect 
in both plasma and liver.  
We next studied the potential mechanisms involved in regulating lipid levels in liver and plasma.  
Because peroxisomes play an important role in modulating hepatic lipid metabolism and subsequent non-
alcoholic fatty liver disease (reviewed in (30)), we analyzed the expression of certain genes involved in 
peroxisomal lipid metabolism and we found that the expression of ABCD-3 and ACOT-3 is significantly 
increased in Indo treated mice.  Moreover, mice treated with both FO and Indo exhibited a greater 
increase in the expression of ABCD-3 and ACOT-3.  In addition, the expression of ACOX-1, another 
peroxisomal gene is significantly increased only in FO + Indo treated mice suggesting that the combined 
treatment is more potent in activating the peroxisomal pathways.  We next analyzed the nuclear extracts 
for the level of PPARα and there was no significant increase in any of the groups compared to control.  
Analysis of hepatic fatty acid oxidation showed that levels of CO2 were reduced significantly whereas 
those of ASMs were increased significantly in FO and FO + Indo groups.  Because the ASMs represent 
the products derived from incomplete oxidation of fatty acids and because peroxisomal pathways result in 
incomplete oxidation products of fatty acids, our data suggest that the peroxisomal lipid metabolism may 
be increased to some extent in FO and FO + Indo treated groups.  However, this effect was not greater in 
FO + Indo treated mice compared to FO alone fed mice.  Therefore, the role of peroxisomal pathways in 
mediating the enhanced lipid-lowering effect of the combination of FO and Indo is unclear.  Analysis of 
TG secretion rate showed that the mice that received both FO and Indo displayed a significant decrease in 
TG secretion rate compared to control suggesting that the enhanced plasma lipid-lowering effect of this 
combination may be due to reduced VLDL secretion into the plasma.   Of note, the mRNA expression of 
FASN was potently reduced in Indo and FO + Indo treated mice.  While the protein level of FASN is not 
altered by Indo treatment it was decreased by combined treatment with FO and Indo (data not shown).             
We next wanted to study the potential biochemical mechanisms by which this combination is beneficial.  
COXs have been implicated in partly mediating the anti-inflammatory effects of n-3 fatty acids (17).  For 
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example, it has been reported that COX-derived -3 fatty acid metabolites such as 3-series TXs and PGs 
are anti-inflammatory or less pro-inflammatory compared to the 2-series eicosanoid metabolites derived 
from AA (17).  However, it has been reported that EPA is a relatively poor substrate for COX (31) and 
moreover DHA, another n-3 fatty acid found in FO, has been shown to be a strong inhibitor of PG 
synthesis (32).  We found that FO feeding greatly reduced AA-derived 2-series TX and PG formation 
which was not associated with an appreciable increase in 3-series eicosanoids in our study.  Furthermore, 
the plasma levels of TXB2 and TXB3 in FO fed mice showed that although the n-3 fatty acids can be 
metabolized by COX to some extent it is not their preferred pathway.    While the role of COX in 
mediating the anti-inflammatory effect of FO is still in debate, our data show that FO in the absence of 
COX activity exhibits a more potent anti-inflammatory effect indicating that COX-derived metabolites of 
n-3 fatty acids may not have a significant role in mediating the anti-inflammatory effect of FO.  
Moreover, these data confirm that COX activity is indeed potently inhibited by Indo in vivo.  It is 
interesting to note that the levels of these eicosanoid metabolites not only correlate with the anti-
inflammatory effects of the combination of FO and Indo but also with their lipid-lowering effects.  
Although the direct effect of these eicosanoids in modulating lipid metabolism is unclear, our data 
indicate that the enhanced anti-inflammatory effect of this combination may have a role in potentiating 
the lipid-lowering effects.   
While modulation of AA metabolism is critical to modulating the inflammatory response by FO or 
COXIBs, it should be noted that AA is metabolized not only via COX activity but also through several 
other pathways.  For example, AA can be metabolized by lipoxygenases and cytochrome P450s, giving 
rise to products which could modulate inflammation.  For example, Serhan et al have shown that certain 
lipoxygenase derived lipid-mediators of AA, the lipoxins, are anti-inflammatory and thus play a role in 
the resolution of inflammatory response (reviewed in(33)).  They have also shown that the n-3 fatty acids 
can produce potent anti-inflammatory agents termed resolvins via lipoxygenase activity (33).  It should 
also be pointed out that the -3 fatty acids can be converted to 5-series leukotrienes via lipoxygenase 
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activity and these are known to be less inflammatory compared to the 4-series leukotrienes that are 
derived from AA.  Therefore, the role of the lipid derivatives produced by these enzymes in mediating the 
enhanced anti-inflammatory effect of the combination of FO and Indo remains possible.   
 As for the CYP pathways, AA can be metabolized by the CYP2C family to epoxy eicosatrienoic acid 
(EET) which is a potent anti-inflammatory mediator (34) and a strong PPAR agonist (35).  Moreover, it 
has been recently shown that such epoxy derivatives can also be produced from n-3 fatty acids (36, 37).  
It is interesting to note that the expression of CYP2C39 which is known to produce EETs (38) is 
significantly increased in mice that received both FO and Indo.  Thus, our data indicate that the enhanced 
CYP-mediated metabolism of n-3 fatty acids may play a role in the synergistic anti-inflammatory effect 
of this combination.   
It should also be pointed out that in addition to modulating the inflammatory response the CYPs play an 
important role in regulating fatty acid and cholesterol metabolism.  For example, CYP4A, a downstream 
target of PPARα is the major regulator of fatty acid -oxidation (39) and our data show that the protein 
level of CYP 4A is significantly increased upon combined treatment with FO and Indo.  Our data also 
show that the expression of PXR and its target gene CYP3A were increased to a greater extent in FO + 
Indo fed mice compared to other groups.  Furthermore, we provide evidence that the activation of PXR, 
as measured by the nuclear levels of this protein, is significantly increased in FO + Indo group compared 
to control.  PXR is originally identified as a xenobiotic sensing nuclear receptor playing a role in drug 
metabolism and it is now well known to play a role in bile acid metabolism (40).  CYP 3A, a PXR target 
is known to regulate drug and bile acid detoxification and recently it has also been shown to promote 
cholesterol catabolism by converting cholesterol to 27-hydroxycholesterol (41).  Thus it is reasonable to 
speculate that the improved cholesterol metabolism in FO + Indo treated mice is mediated through PXR 
and CYPs.   In fact, based on their role in regulating cholesterol homeostasis, it has been postulated that 
CYPs may serve as the therapeutic targets for cholesterol lowering drugs (42) and our data support this 
notion.  Although our data point to the role of PXR in mediating the hypolipidemic effects of this 
18 
 
combination, the role of constitutive androstane receptor (CAR), another nuclear receptor which acts in 
co-ordination with PXR cannot be ruled out.   
 
Taken together, our data that FO increases adiposity, the formation of ASMs in liver, and the expression 
of PXR, suggest that the improved lipid storage in adipose tissue and the increased lipid catabolism in 
liver play a role in reducing the fasting free fatty acid levels in plasma and/or the overall lipid-lowering 
effect of FO.  While FO is a well-known lipid-lowering agent, the effect of Indo in modulating lipid 
metabolism has not been clearly elucidated.  Pratico et al have shown that Indo treatment for 18 weeks 
led to a mild reduction in plasma TC in LDLR-/- mice (20).   In line with this, our data provide evidence 
for the role for NSAIDs, like Indo in improving plasma lipid and lipoprotein profiles in dyslipidemic 
mice.  As for hepatic steatosis, Indo was shown to increase hepatic lipid metabolism and prevent hepatic 
lipid accumulation in a mouse model of cancer (43).  Our data show that Indo blunts the accumulation of 
both CE and TG in the liver.  This effect is associated with a significant decrease in plasma TC and TG in 
LDLR-/- mice (Table 1).   
With regard to potential mechanisms, our data show that Indo treated mice exhibit an increased mRNA 
expression of peroxisomal genes such as ABCD-3 and ACOT-3.  On the other hand, the fatty acid -
oxidation measured using [1-14C]-palmitic acid is not altered in these mice.  However, it should be noted 
that in vivo peroxisomal metabolism of fatty acids leads only to chain shortening but not in complete fatty 
acid oxidation.  Moreover, we only used palmitic acid as a substrate for -oxidation and therefore, the 
condition is not exactly mimicking the in vivo conditions.  Therefore, it is reasonable to speculate that the 
peroxisomal pathways may still be involved in mediating the lipid-lowering effect of Indo.  It should also 
be pointed out that the protein expression of PXR is increased upon Indo treatment.  As PXR is involved 
in both drug and cholesterol metabolism, it is possible that PXR may also have a role in mediating the 
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hypolipidemic effect of Indo.  However, further studies are warranted to determine the specific role of 
peroxisomal fatty acid oxidation and PXR in mediating the hypolipidemic effects of Indo.   
While combination therapy using different drugs is frequently employed in clinical practice, our data 
suggest that combining FO with Indo may be an effective strategy to combat dyslipidemia and hepatic 
steatosis.  While several beneficial effects are noted in the current study, it should be pointed out that the 
plasma TC and liver CE were reduced by an additional 21% and 30%, respectively, in mice that received 
a combination of FO and Indo compared to mice that received FO only.  Moreover, unlike statins which 
reduce only plasma TC (44), this combination appears to be beneficial in reducing both TC and TG.  
Furthermore, we noted an overall decrease in hepatic inflammation in mice that received a combination of 
FO and Indo further indicating the safety of this combination.  It should also be pointed out that our 
experimental diet contained 6% fish oil which provides twice as much the maximum dose (4g per day) of 
n-3 fatty acids as recommended in clinical settings.  To better understand the efficacy of combination 
therapy further studies are needed using lower amount of fish oil in the diet. 
In summary, our data suggest that a combination of FO and Indo mediates enhanced lipid-lowering 
effects in plasma and liver via several mechanisms including increased lipid accumulation in perigonadal 
fat, increased hepatic lipid metabolism via PXR and CYP activities, and reduced TG-secretion from liver.  
However, the mechanisms by which Indo mediates its lipid-lowering effects are still unclear and future 
studies are needed to determine the exact mechanisms by which Indo, an anti-inflammatory agent, exerts 
its hypolipidemic effect.  Our findings have implications in considering a combination of FO and 
COXIBs as a potential therapeutic regimen to treat patients with dyslipidemia and in particular, FH, who 
are at an increased risk of developing premature CVD.   
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 FOOTNOTES  
*The microarray data have been deposited in the public genomic data repository (GEO accession number: 
GSE23742).  These data are available at http://www.ncbi.nlm.nih.gov/geo).  
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FIGURE LEGENDS 
 
Figure 1:  Lipoprotein distribution in LDLR-/- mice fed a FO diet in the presence or absence of 
Indo.   
Plasma lipoproteins were separated by gel filtration chromatography to determine cholesterol distribution.   
Fractions containing VLDL, LDL, and HDL are indicated on graph.  
Figure 2:  Effect of FO in the presence or absence of Indo on hepatic steatosis 
Hepatic content of cholesterol esters (A), and triglycerides (B), free cholesterol (C), and free fatty acids 
(D)  were measured by gas chromatography (n=5-10).   Data are plotted as mean ± SEM of 5-10 per 
group.  Cholesterol ester (CE), Triglycerides (TG), free cholesterol (FC), and free fatty acids (FFA).  
Figure 3:  Effect of FO in the presence or absence of Indo on genes involved in lipid metabolism in 
liver 
RNA samples were analyzed by real time PCR for the expression of genes modulating lipid metabolism 
(A-H).  Values are expressed as mean ± SEM of six samples in each group.   
Figure 4:  Effect of FO in the presence or absence of Indo on the mRNA and protein expression of 
genes involved in lipid or drug metabolism in liver 
RNA samples were analyzed by real time PCR for the expression of genes modulating lipid or drug 
metabolism (A-C).  Values are expressed as mean ± SEM of six samples in each group. Liver 
homogenates were analyzed by western blot analysis for the protein expression of genes modulating lipid 
or drug metabolism (D-G).  Bands from two samples in each group are shown.  Values are expressed as 
mean ± SEM of six samples in each group.   
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Figure 5:  Effect of FO in the presence or absence of Indo on factors modulating lipid levels in liver 
and plasma.  Nuclear extracts were prepared from liver samples and western blot analysis was carried 
out to detect the activation of PPARα and PXR (A-C).  TBP was used as a loading control and a 
representative band from each group is shown.  The rate of -oxidation was measured using [14C] palmitic 
acid (D-F).  The TG secretion rate was studied by injecting Triton, a lipoprotein lipase inhibitor, and 
measuring plasma TG levels over a 3 h period (G).  Values are mean ± SEM of 6-7 samples in each 
group.   
Figure 6:  Effect of FO in the presence or absence of Indo on genes involved in inflammatory 
response 
RNA samples were analyzed by real time PCR for the expression of genes modulating the inflammatory 
response (A-F).  Values are expressed as mean ± SEM of six samples in each group.   
Figure 7:  Effect of FO in the presence or absence of Indo on genes involved in inflammatory 
response and/or lipid metabolism in perigonadal AT and BAT 
RNA samples were analyzed by real time PCR for the expression of genes modulating the inflammatory 
response in perigonadal AT (A&B) and, inflammatory response and lipid metabolism BAT (C-F).  Values 
are mean ± SEM of 6-7 samples in each group.   
Figure 8:  Effect of FO in the presence or absence of Indo on the levels of various COX-derived 
eicosanoids in liver and plasma 
Liver samples were analyzed for the levels of 2- and 3-series PGs and TXs by mass spectrometry (A-F).  
Values are expressed as mean ± SEM of six samples in each group.  Ionomycin induced TXB2 formation 
in blood is measured by mass spectrometry (G-I).  Values are mean ± SEM of 9-14 samples in each 
group.  
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Table 1: Effect of FO and/or Indo on metabolic parameters in LDLR-/- mice 
Measurements Olive Oil                 FO Olive Oil +           FO + Indo                     Indo 
 
Body Weight (g) 
 
Liver weight (g) 
 
Cumulative Food Intake 
(g/mouse/wk) 
 
Fat mass (g) 
 
Adiposity (% body weight) 
 
Perigonadal fat mass (g) 
 
Glucose (mg/dL) 
 
Insulin (µg/L) 
 
HOMA-IR 
 
Total Cholesterol (TC, mg/dL) 
 
Cholesterol Ester (CE, mg/dL) 
 
Unesterified Cholesterol (UC, 
 
23.6 ± 0.8 
 
1.43 ± 0.10 
 
52.5 ± 2.9 
 
3.09 ± 0.31 
 
12.6 ± 1.0 
 
0.34 ± 0.03 
 
231 ±  23 
 
0.47 ± 0.06 
 
6.12 ± 0.92 
 
572 ± 21 
 
638 ± 43 
 
210 ± 23 
 
24.7 ± 0.8 
 
1.38 ± 0.06 
 
60.0 ± 4.1 
 
4.41 ± 0.38 
 
19.0 ± 1.5d 
 
0.52 ± 0.06 
 
195 ± 17 
 
0.52 ± 0.05 
 
6.74 ± 0.78 
 
393 ± 24b 
 
489 ± 38 
 
150 ± 9.7 
 
23.7 ± 0.5 
 
1.58 ± 0.05 
 
53.2 ± 3.3 
 
2.89 ± 0.23 
 
12.8 ± 1.1 
 
0.37 ± 0.03 
 
225 ± 13 
 
0.54 ± 0.05 
 
8.02 ± 1.19 
 
469 ± 19a 
 
651 ± 42 
 
194 ± 37 
 
24.2 ± 1.0 
 
1.41 ± 0.07 
 
50.2 ± 1.3 
 
4.59 ± 0.78 
 
17.8 ± 2.3 
 
0.59 ± 0.10a 
 
246 ± 23 
 
0.54 ± 0.06 
 
7.96 ± 1.32 
 
311 ± 19bc 
 
378 ± 35a 
 
105 ± 11.7 
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aP<0.01, and bP<0.001, vs olive oil; cP<0.05 vs FO; dP<0.05 vs olive oil and olive oil + Indo.  Values are 
presented as mean ± SEM from 11-15 mice in each group for all the analyses except food intake, CE, UC, 
and PL.  Food intake was measured in two cages in each group and CE, UC, and PL were analyzed using 
GC method and values are mean ± SEM of 4-6 samples in each group.   
 
 
 
 
 
 
 
 
 
 
 
 
 
mg/dL) 
 
Triglycerides (TG, mg/dL) 
 
Phospholipids (PL, mg/dL) 
 
Free Fatty Acids (FFA, mEq/L) 
 
 
209 ± 18 
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Table 2:  Number of genes up or downregulated in FO, Indo, or FO + Indo received mice 
Biological Function Number of genes upregulated        Number of genes downregulated 
FO Indo FO + 
Indo 
FO Indo FO + 
Indo 
Lipid metabolism 2 22 51 9 2 11 
Drug/lipid metabolism (CYPs) 2 3 9 0 0 3 
Inflammatory response 1 34 15 41 1 52 
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